Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.78 USD | +0.53% | +2.16% | +42.64% |
Mar. 20 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Mar. 20 | Sector Update: Health Care Stocks Down Wednesday Afternoon | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,183 | 572.9 | 148.4 | 213.6 | - | - |
Enterprise Value (EV) 1 | 884 | 242.5 | 148.4 | -17.35 | 45.85 | 213.6 |
P/E ratio | -27.8 x | -9 x | -2.23 x | -2.99 x | -2.59 x | -2.42 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -24,759,117 x | -3,609,892 x | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 55,232 | 55,841 | 56,000 | 56,495 | - | - |
Reference price 2 | 21.41 | 10.26 | 2.650 | 3.780 | 3.780 | 3.780 |
Announcement Date | 3/10/22 | 3/14/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | -35.7 | -67.19 | - | - | - | - |
EBIT 1 | - | -35.83 | -67.59 | -78.19 | -76.31 | -92.64 | -103.4 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -35.53 | -63.31 | -66.86 | -87.51 | -105.7 | -116.2 |
Net income 1 | -8.28 | -35.53 | -63.31 | -66.86 | -73.11 | -87.78 | -116.2 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -0.5216 | -0.7700 | -1.140 | -1.190 | -1.265 | -1.460 | -1.560 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/5/21 | 3/10/22 | 3/14/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -11.34 | -11.13 | -13.37 | -15.64 | -19.19 | -19.39 | -21.65 | -22.6 | -18.82 | -15.12 | -16.91 | -18.33 | -19.72 | -21.35 | -25.96 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -11.32 | -11.06 | -13.26 | -15 | -17.7 | -17.34 | -19.29 | -19.94 | -15.79 | -11.84 | -17.94 | -20.63 | -23.24 | -25.7 | -25.96 |
Net income 1 | -11.32 | -11.06 | -13.26 | -15 | -17.7 | -17.34 | -19.29 | -19.94 | -15.79 | -11.84 | -16.07 | -17.57 | -19.02 | -20.45 | -25.96 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2100 | -0.2000 | -0.2400 | -0.2700 | -0.3200 | -0.3100 | -0.3500 | -0.3600 | -0.2800 | -0.2100 | -0.2800 | -0.3050 | -0.3250 | -0.3500 | -0.4300 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/9/21 | 3/10/22 | 5/9/22 | 8/8/22 | 11/3/22 | 3/14/23 | 5/9/23 | 8/14/23 | 11/13/23 | 3/19/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 299 | 330 | - | 231 | 168 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/5/21 | 3/10/22 | 3/14/23 | 3/19/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.64% | 214M | |
+1.51% | 42.75B | |
+47.98% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- DSGN Stock
- Financials Design Therapeutics, Inc.